Novel target platform for metabolic inflammation, fibrosis and inflammasome pathologies
The Elgia team has discovered how metabolic stress drives inflammation and fibrosis and has identified untapped protein targets for small molecule drug discovery. By combining these pioneering biological insights with R&D expertise, Elgia is creating innovative medicines for debilitating chronic diseases.
Keystones of Elgia’s Unique Drug Discovery Platform
Extraordinary
Biology Insight
Intersection of untapped biology, unique MOA, efficacy, and safety
Disease and Drug
Discovery Depth
Exceptional foundation for drug discovery from combined experience of leadership
Highly Enabled
Drug Development
Advanced chemical matter, SBDD and clinical know-how to move assets quickly
Expansive Pipeline
Opportunities
Multiple clinical applications
for metabolic, inflammatory
and fibrotic diseases
Positioned to deliver first-in-class and best-in-class therapies
The Elgia approach to controlling inflammation and fibrosis is anchored in the deep knowledge of caspase and kinase molecular targets and the roles played in chronic diseases.